The Swiss pharmaceutical company Relief Therapeutics and its partner NeuroRx have applied for emergency approval for an experimental corona drug in the USA. The drug Aviptadil (RLF-100) is to be used in patients with Covid-19 at a critical stage who have exhausted all approved therapies. The application for approval with the FDA is based on a case-control study. According to Relief, patients in intensive care units treated with Aviptadil had better outcomes for respiratory failure recovery and survival than standard therapy.